UCB SA (FRA:UNC)
Germany · Delayed Price · Currency is EUR | Market Cap | 47.97B +39.6% |
| Revenue (ttm) | 7.74B +25.8% |
| Net Income | 1.56B +46.3% |
| EPS | 8.03 +46.5% |
| Shares Out | n/a |
| PE Ratio | 30.79 |
| Forward PE | 23.34 |
| Dividend | 0.97 (0.39%) |
| Ex-Dividend Date | Apr 25, 2025 |
| Volume | n/a |
| Average Volume | 15 |
| Open | 251.40 |
| Previous Close | 251.40 |
| Day's Range | 251.40 - 251.40 |
| 52-Week Range | 135.90 - 285.40 |
| Beta | n/a |
| RSI | 46.95 |
| Earnings Date | Jul 30, 2026 |
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for... [Read more]
Financial Performance
In 2025, UCB SA's revenue was 7.74 billion, an increase of 25.83% compared to the previous year's 6.15 billion. Earnings were 1.56 billion, an increase of 46.29%.
Financial StatementsNews
UCB SA Reports Long-Term Bimzelx Data In Hidradenitis Suppurativa
(RTTNews) - UCB S.A. (UCBJY) announced on Friday that it has presented new post hoc data regarding Bimzelx (bimekizumab) at the American Academy of Dermatology Annual Meeting 2026 held in Denver, whic...
Ex-Div Reminder for United Community Banks (UCB)
Looking at the universe of stocks we cover at Dividend Channel, on 3/13/26, United Community Banks Inc (Symbol: UCB) will trade ex-dividend, for its quarterly dividend of $0.25, payable on 4/3/26. As ...
UCB's Bimzelx Outperforms AbbVie's Skyrizi in Psoriatic Arthritis Trial
UCB's Bimzelx Outperforms AbbVie's Skyrizi in Psoriatic Arthritis Trial
Belgium's UCB in autoimmune drug deal with Antengene
Belgian drugmaker UCB has entered into an agreement to licence Antengene's experimental autoimmune disease therapy ATG-201 and associated technology, paying $60 million up front and over $1.1 billio...
UCB SA (UCBJF) (FY 2025) Earnings Call Highlights: Record Growth and Strategic Investments ...
UCB SA (UCBJF) (FY 2025) Earnings Call Highlights: Record Growth and Strategic Investments Propel Future Prospects
Full Year 2025 Ucb SA Earnings Call Transcript
Full Year 2025 Ucb SA Earnings Call Transcript
Best Income Stocks to Buy for March 2nd
CZNC, UCB and CRI made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 2, 2026.
U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)
Approved indication: KYGEVVI® (doxecitine and doxribtimine) powder for oral solution (2g/2g) is approved for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with...